{
    "eid": "2-s2.0-85160928843",
    "title": "Virus-induced senescence: A therapeutic target to mitigate severe progression of SARS-COV-2",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Clinical Biochemistry",
            "@code": "1308",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "COVID-19",
        "COVID-19 therapeutics",
        "global pandemic",
        "SARS-CoV-2",
        "senolytic drugs"
    ],
    "authors": [
        "Mani Iyer Prasanth",
        "James Michael Brimson",
        "Tewin Tencomnao"
    ],
    "citedby-count": 0,
    "ref-count": 23,
    "ref-list": [
        "COVID-19 as the leading cause of death in the United States",
        "The economic effects of COVID-19 containment measures",
        "COVID-19 vaccines adverse events: potential molecular mechanisms",
        "COVID-19: a state of art on immunological responses, mutations, and treatment modalities in riposte",
        "Cellular senescence: beneficial, harmful, and highly complex",
        "Cellular senescence in immunity against infections",
        "Inflammation in COVID-19: from pathogenesis to treatment",
        "Senolytics reduce coronavirus-related mortality in old mice",
        "Novel SARS-CoV-2 therapeutic targets: RNA proofreading complex and virus-induced senescence",
        "COVID-19 and cellular senescence",
        "B. 1.617. 2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination",
        "The struggle of a good friend getting old: cellular senescence in viral responses and therapy",
        "Cell senescence is an antiviral defense mechanism",
        "Virus-induced senescence is a driver and therapeutic target in COVID-19",
        "SARS-CoV-2 causes senescence in human cells and exacerbates the senescence-associated secretory phenotype through TLR-3",
        "Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm",
        "SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response",
        "Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cells",
        "Rapamycin golden jubilee and still the miraculous drug: a potent immunosuppressant, antitumor, rejuvenative agent, and potential contributor in COVID-19 treatment",
        "Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice",
        "Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19",
        "Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial",
        "SARS-CoV-2 infection aggravates chronic comorbidities of cardiovascular diseases and diabetes in mice"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": []
}